Bristol-Myers files for Japanese approval of first all-oral hep C treatment; Novogen, Yale tackle ovarian cancer drug delivery together;

> Bristol-Myers Squibb ($BMY) filed with Japanese health regulators to approve its all-oral hepatitis C treatment, the first of its kind. Story

> Novogen and Yale launched a joint venture to develop treatments for ovarian cancer that use a delivery model created by a Yale professor. More

> Zogenix entered a development and option agreement with Altus Formulation for Zogenix's extended-release hydrocodone and Altus' delivery platform. More

> Aphios won a U.S. patent for its nanoencapsulated oral delivery platform for cannabinoids to treat pain in cancer and AIDS patients. More